Market Access Capabilities
Ipsos Market Access
Introduction Video
Ipsos Market Access
Overview by Richard Tolley
Ipsos Market Access
Global CoE Overview
Market Foresight, Competitive Simulation, War Gaming
Payer
Trackers
Quantitative
Pricing
Willingness
to Pay
Rapid Payer Insights
Overview
Ipsos Market Access
Capabilities Summary 2024
Non-interventional Study Capabilities
Ipsos ASCVD Payer and KOL Study
Payer Pulse Pro Rapid Payer Insight Capability
Thought Leadership
Pricing & Access Challenges in the Absence of Data: EPA Conference 2021
The Future of Pharmaceutical
Pricing
The Power of Payer Insights Tracking in Times of Turbulence & Market Disruption
Changing Paradigms: The Past, Present & Future of Autoimmune Treatment
Major Future Evidence Pricing & Access Challenges and how to overcome them - An Ipsos POV
The Power of Holistic
Insight
The Future of
Market Access
Ipsos Healthcare Hot Seat Book of Inspiration
Using RWE to Leverage Pricing and Access
Unrealised Potential of Digital Therapeutics
Integration of wearables data
with payer evidence strategy
Ipsos Digital and
Connected Health
Addressing the top 10 Evidence
Pricing Access Challenges
Five Manoeuvres to Maximise your Medtech Launch
Five Steps to Evidence
and Access
Four Areas of Intersection for RWE and Market Access
Digital Health and Reduce Burden of Illness
AI,molecular diagnostics, &
their role in optimizing disease management
Oncology Challenges Workshop Summary
Information Asymmetry Presentation
ISPOR Posters
ISPOR 2021 � The Monitor Intervene Predict Value Framework
ISPOR 2021 � Legislative Proposal for Joint Work on EU
ISPOR 2021 � Leveraging RWE & Integrating Multi-Source Data
ISPOR 2021 � Reimbursement of Gene Therapies
ISPOR 2021 - Understanding Value Drivers of EU Payers� Evaluation of Products that Combine Drugs, Devices and Digital Health
ISPOR 2021 - Understanding the Impact of CSU and What is Most Important to Patients
ISPOR 2021 - Delayed Reimbursement Decisions due to Increased Budgetary Pressures in Eastern Europe
ISPOR 2023_Use of Patient Preference Studies in NICE Submissions in the Last 5 years
ISPOR 2023_Similarities and differences in Health Technology Assessment (HTA) bodies considerations for decision-making: Use of Patient Preference studies
ISPOR 2023_EU Joint Clinical Assessments On Health Technologies Is Approaching – Are We Prepared?
ISPOR 2023_What Must Change If Future Evidence Pricing And Access Challenges Are To Be Successfully Overcome?
Wider Ipsos Healthcare Capabilities
Global Oncology Monitor
Overview 2023
Global Therapy Monitor
Overview 2023
Syndicated
RWE Compendium 2023
